SPL
AGMB icon

Superior Planning, LLC’s AgomAb Therapeutics NV AGMB Stock Holding History

Superior Planning, LLC’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$844 Buy
+76
New +$983 ﹤0.01% 1786

Other funds holding AGMB

EQT Fund Management
EQT Fund Management Luxembourg $947M AUM 19.95% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Superior Planning, LLC's AGMB Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in AgomAb Therapeutics NV (AGMB) in Q3 2026: 76 shares worth $844. The stake represents ﹤0.01% of the portfolio and ranks #1786 among its holdings.

19 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • Superior Planning, LLC held 76 shares of AgomAb Therapeutics NV worth $844 as of Q3 2026.
  • AgomAb Therapeutics NV was a new Superior Planning, LLC position in Q3 2026.
  • AgomAb Therapeutics NV made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1786 holding.
  • 19 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.